Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy

Chiara De Waure, Stefano Capri, Maria Assunta Veneziano, Maria Lucia Specchia, Chiara Cadeddu, Francesco Di Nardo, Anna Maria Ferriero, Francesca Gennari, Colette Hamilton, Agostino Mancuso, Gianluigi Quaranta, Matteo Raponi, Luca Valerio, Gianfranco Gensini, Walter Ricciardi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

19 Citazioni (Scopus)


OBJECTIVES: To develop a comparative, cost-effectiveness, and budget impact analysis of Therakos online extracorporeal photopheresis (ECP) compared with the main alternatives used for the treatment of steroid-refractory/resistant chronic graft-versus-host disease (cGvHD) in Italy. METHODS: The current therapeutic pathway was identified by searching medical databases and from the results of a survey of practice in Italian clinical reference centers. A systematic review was performed to evaluate the efficacy and safety of second-line alternatives. Budget impact and cost-effectiveness analyses were performed from the Italian National Health Service perspective over a 7-year time horizon through the adaption of a Markov model. The following health states were considered: complete and partial response, stable disease, and progression. A discount rate of 3% was applied to costs and outcomes. RESULTS: The most common alternatives used in Italy for the management of steroid-refractory/resistant cGvHD were ECP, mycophenolate, pentostatin, and imatinib. The literature review highlighted that complete and partial responses are higher with ECP than with the alternatives while serious adverse events are less common. The economic analysis showed that Therakos online ECP represents the dominating alternative, in that it delivers greater benefit at a lower cost. In fact, according to the alternatives considered, cost saving ranged from €3237.09 to €19,903.51 per patient with 0.04 to 0.21 quality-adjusted life-year gained. CONCLUSIONS: Therakos online ECP should be considered an effective, safe, and cost-effective alternative in steroid-refractory/resistant cGvHD. There is inequality in access, and a dedicated reimbursement tariff, however, should be introduced to overcome these barriers.
Lingua originaleEnglish
pagine (da-a)457-466
Numero di pagine10
RivistaValue in Health
Stato di pubblicazionePubblicato - 2015


  • Chronic Graft-versus-Host Diseases
  • Extracorporeal Photopheresis
  • Health Technology Assessment


Entra nei temi di ricerca di 'Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy'. Insieme formano una fingerprint unica.

Cita questo